Stoke Therapeutics (NASDAQ:STOK) CFO Sells $72,489.96 in Stock

Key Points

• CFO Thomas Leggett sold 2,196 shares on March 17 at an average $33.01 (~$72,489.96) and 2,382 shares on March 18 at $31.34 (~$74,651.88), trimming his stake by 14.89% to 12,554 shares (≈$414,408).
• STOK rallied about 7.0% to $33.19 on higher volume as multiple brokerages raised targets or reaffirmed buys, with a MarketBeat consensus rating of "Moderate Buy" and an average price target of $39.83.
• Offsetting optimism, the company missed quarterly expectations (EPS -$0.97 vs. -$0.75 consensus; revenue $1.4M vs. $5.3M expected) and granted inducement stock options that could add future dilution risk.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) CFO Thomas Leggett sold 2,196 shares of the company's stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $33.01, for a total transaction of $72,489.96. Following the completion of the transaction, the chief financial officer owned 12,554 shares of the company's stock, valued at approximately $414,407.54. The trade was a 14.89% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Thomas Leggett also recently made the following trade(s):

• On Wednesday, March 18th, Thomas Leggett sold 2,382 shares of Stoke Therapeutics stock. The stock was sold at an average price of $31.34, for a total transaction of $74,651.88.

Stoke Therapeutics Stock Up 7.0%

STOK traded up $2.17 on Thursday, reaching $33.19. The company had a trading volume of 853,428 shares, compared to its average volume of 754,489. Stoke Therapeutics, Inc. has a 1 year low of $5.35 and a 1 year high of $40.22. The stock has a market capitalization of $1.96 billion, a PE ratio of 49.54 and a beta of 1.07. The stock has a 50-day moving average price of $32.61 and a 200-day moving average price of $29.90.

Analyst Ratings Changes

A number of brokerages recently issued reports on STOK. HC Wainwright upped their target price on Stoke Therapeutics from $35.00 to $50.00 and gave the company a "buy" rating in a research report on Monday, December 15th. Needham & Company LLC lifted their price target on Stoke Therapeutics from $35.00 to $40.00 and gave the stock a "buy" rating in a research report on Tuesday. Wedbush boosted their price objective on Stoke Therapeutics from $36.00 to $38.00 and gave the company an "outperform" rating in a research note on Tuesday. Canaccord Genuity Group increased their price objective on Stoke Therapeutics from $28.00 to $36.00 and gave the company a "buy" rating in a report on Monday, January 5th. Finally, Guggenheim initiated coverage on shares of Stoke Therapeutics in a report on Thursday, February 5th. They issued a "buy" rating and a $60.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $39.83.

Key Stories Impacting Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Multiple analysts raised or reiterated bullish ratings and price targets this week (BTIG reaffirmed "buy" with a $39 target; Wedbush lifted its target to $38; Needham raised its target toward $40 and Chardan keeps a $35 target) — these actions increase buy-side interest and provide technical/supportive buying. Read More.
• Positive Sentiment: Pipeline story: coverage highlighting STK‑001’s potential to restore developmental deficits in Dravet syndrome (beyond seizure control) supports upside for long-term clinical value if trials continue to show benefit. Read More.
• Neutral Sentiment: Company granted inducement stock options to new hires — helps recruiting but adds potential future dilution; not an immediate earnings impact. Read More.
• Negative Sentiment: Quarterly results missed expectations: EPS of ($0.97) vs. consensus ($0.75) and revenue $1.4M vs. $5.3M expected — the earnings/revenue shortfall is the clearest near-term driver of prior downward pressure and investor concern about near-term commercialization/visibility. Read More.
• Negative Sentiment: Insider sale disclosed — Director Arthur A. Levin sold 605 shares (~$22k) in mid‑March; small in dollar terms but sometimes interpreted as a mild negative signal by short‑term traders. Read More.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in STOK. Kestra Advisory Services LLC acquired a new position in Stoke Therapeutics in the 4th quarter valued at about $26,000. Harbour Investments Inc. lifted its position in Stoke Therapeutics by 312.9% during the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company's stock worth $38,000 after acquiring an additional 898 shares during the period. Generali Investments Management Co LLC acquired a new stake in Stoke Therapeutics during the 3rd quarter worth approximately $41,000. BNP Paribas Financial Markets grew its stake in shares of Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company's stock valued at $48,000 after purchasing an additional 1,668 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Stoke Therapeutics by 461.0% in the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company's stock valued at $50,000 after purchasing an additional 3,591 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.